-The Times of India NEW DELHI: In a move to ensure efficacy of medicines sold in India, the drug regulator has made it mandatory for companies to include Indian patients in global clinical trials if they want to market in India a new drug developed outside the country. The decision was taken in a recent technical committee meeting, headed by director general of health services Jagdish Prasad. The committee, which was formed...
More »SEARCH RESULT
Total Matching Records found : 156
Centre set to roll out new treatment for encephalitis -Jacob Koshy
-The Hindu Acne drug seen to provide cure for Japanese encephalitis in limited trials Weeks after several children died of encephalitis-related complications at the Baba Raghav Das (BRD) Medical College, Gorakhpur, the Centre is looking to introduce a new drug, traditionally used for acne, to deal with the seasonal outbreaks of acute encephalitis. Last year the Indian Council of Medical Research (ICMR) said the drug did not appear potent enough to merit being...
More »Generic medicines in a digital age -Dinesh S Thakur & Prashant Reddy T
-The Hindu We need a legal mechanism to ensure that all generics are of the same standard as the innovator product The Prime Minister’s recent announcement on making it mandatory for doctors to prescribe only the generic name, and not brand name of a drug, has led to a flutter. If enacted, the move will make it illegal for Indian doctors to write out a prescription for the trademark of the drug,...
More »Cheap generic vs costly branded: Issues in picking right drug in India -Kaunain Sheriff M
-The Indian Express Prime Minister Narendra Modi wants doctors to prescribe generic medicines over branded ones. KAUNAIN SHERIFF M answers key questions on the pricing of drugs and beyond. * What exactly has Prime Minister Narendra Modi said on generic drugs? Speaking in Surat on April 17, the Prime Minister referred to the Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP), which aims to provide cheaper medical drugs to the people. “In the coming days,...
More »Generics vs big pharma, reloaded -Shamnad Basheer
-The Hindu The proposal to extend the time limit for State-level drug regulatory approvals from four to 10 years could hit the generics market In a scathing letter to the Government of India, the Indian Pharmaceutical Alliance (IPA) took issue with what it considered to be a backdoor extension for data exclusivity norms in the country. It pointed to the recent government proposal to change the four-year time limit for State-level drug...
More »
